Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest Up 120.7% in July

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,746,865 shares, a growth of 120.7% from the June 30th total of 1,697,593 shares. Based on an average daily volume of 686,566 shares, the days-to-cover ratio is currently 5.5 days. Approximately 9.6% of the shares of the company are sold short.

Coeptis Therapeutics Stock Performance

Shares of ZSQR opened at $5.29 on Thursday. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a 52-week low of $4.32 and a 52-week high of $21.41. The company has a 50-day simple moving average of $9.62 and a 200-day simple moving average of $11.51. The company has a market capitalization of $272.06 million, a PE ratio of -2.10 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The company had revenue of $0.11 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP acquired a new position in Coeptis Therapeutics during the fourth quarter worth about $259,000. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares during the last quarter. Geode Capital Management LLC increased its position in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.